XML 30 R21.htm IDEA: XBRL DOCUMENT
v3.23.2

Description of Business - Additional Information (Details) - Metacrine, Inc. [Member] - Metacrine's FXR Program [Member] | 12 Months Ended
--- | ---
Mar. 31, 2023 Compounds
Description Of Business And Summary Of Significant Accounting Policies [Line Items] |
Number of clinically tested compounds | 2
Number of discovery or preclinical compounds | 2,000

X
- Definition Description of business and summary of significant accounting policies. + References No definition available. + Details
Name: | onvo_DescriptionOfBusinessAndSummaryOfSignificantAccountingPoliciesLineItems
Namespace Prefix: | onvo_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of clinically tested compounds. + References No definition available. + Details
Name: | onvo_NumberOfClinicallyTestedCompounds
Namespace Prefix: | onvo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of discovery or preclinical compounds. + References No definition available. + Details
Name: | onvo_NumberOfDiscoveryOrPreclinicalCompounds
Namespace Prefix: | onvo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=onvo_MetacrineIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=onvo_MetacrinesFxrProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |